Patterns of use of biological and genetic markers for chronic lymphocytic leukemia and acute myeloid leukemia in Puerto Rico

被引:1
作者
Ortiz-Ortiz, Karen J. J. [1 ,2 ,3 ]
Torres-Cintron, Carlos R. R. [2 ]
Ramos, Tonatiuh Suarez [2 ]
Castaneda-Avila, Maira A. A. [4 ]
Cotto Santana, Luis A. A. [5 ]
Tortolero-Luna, Guillermo [1 ,2 ]
机构
[1] Univ Puerto Rico, Div Canc Control & Populat Sci, Comprehens Canc Ctr, POB 363027, San Juan, PR 00925 USA
[2] Univ Puerto Rico, Comprehens Canc Ctr, Puerto Rico Cent Canc Registry, San Juan, PR USA
[3] Univ Puerto Rico, Grad Sch Publ Hlth, Dept Hlth Serv Adm, Med Sci Campus, San Juan, PR USA
[4] Univ Massachusetts, Dept Populat & Quantitat Hlth Sci, Chan Med Sch, Worcester, MA USA
[5] Auxilio Mutuo Hosp, San Juan, PR USA
来源
CANCER MEDICINE | 2023年 / 12卷 / 06期
关键词
acute myeloid leukemia (AML); genetic markers; chronic lymphocytic leukemia (CLL); Hispanics; Puerto Rico; INTERNATIONAL PROGNOSTIC INDEX; WORLD CLINICAL-EXPERIENCE; MUTATION STATUS; GENOMIC ABERRATIONS; PROSPECTIVE COHORT; COMORBIDITY INDEX; IDH2; MUTATIONS; AML; 10; CLL; SURVIVAL;
D O I
10.1002/cam4.5482
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundThe use of markers has stimulated the development of more appropriate targeted therapies for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). We assessed the use and prevalence of biological and genetic markers of CLL and AML in the homogeneous Hispanic population of Puerto Rico. MethodsWe used the Puerto Rico CLL/AML Population-Based Registry, which combines information from linked databases. Logistic regression models were used to examine factors associated with biological and genetic testing. ResultsA total of 926 patients 18 years or older diagnosed with CLL (n = 518) and AML (n = 408) during 2011-2015 were included in this analysis. Cytogenetic testing (FISH) was reported for 441 (85.1%) of the CLL patients; of those, 24.0% had the presence of trisomy 12, 9.5% carried deletion 11q, 50.3% carried deletion 13q, and 6.3% carried deletion 17p. Regarding AML, patients with cytogenetics and molecular tests were considered to determine the risk category (254 patients), of which 39.8% showed poor or adverse risk. Older age and having more comorbidities among patients with CLL were associated with a lower likelihood of receiving a FISH test. ConclusionsAlthough prognostic genetic testing is required for treatment decisions, the amount of testing in this Hispanic cohort is far from ideal. Furthermore, some tests were not homogeneously distributed in the population, which requires further exploration and monitoring. This study contributes to the field by informing the medical community about the use and prevalence of biological and genetic markers of CLL and AML. Similarly, it has the potential to improve the management of CLL and AML through benchmarking.
引用
收藏
页码:6889 / 6901
页数:13
相关论文
共 65 条
  • [1] Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways
    Abruzzo, Lynne V.
    Herling, Carmen D.
    Calin, George A.
    Oakes, Christopher
    Barron, Lynn L.
    Banks, Haley E.
    Katju, Vikram
    Keating, Michael J.
    Coombes, Kevin R.
    [J]. HAEMATOLOGICA, 2018, 103 (12) : 2069 - 2078
  • [2] Biomarkers in chronic lymphocytic leukemia: Clinical applications and prognostic markers
    Amaya-Chanaga, Carlos I.
    Rassenti, Laura Z.
    [J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2016, 29 (01) : 79 - 89
  • [3] Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review
    Autore, Francesco
    Strati, Paolo
    Laurenti, Luca
    Ferrajoli, Alessandra
    [J]. HAEMATOLOGICA, 2018, 103 (06) : 931 - 938
  • [4] Ayatollahi Hossein, 2017, Hematol Oncol Stem Cell Ther, V10, P1, DOI 10.1016/j.hemonc.2016.08.005
  • [5] Management of Chronic Lymphocytic Leukemia in the Elderly
    Barrientos, Jacqueline C.
    [J]. CANCER CONTROL, 2015, 22 (04) : 17 - 23
  • [6] Bendari Mounia, 2018, Open Access Maced J Med Sci, V6, P2328, DOI 10.3889/oamjms.2018.484
  • [7] Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia:: results from Cancer and Leukemia Group B (CALGB 8461)
    Byrd, JC
    Mrózek, K
    Dodge, RK
    Carroll, AJ
    Edwards, CG
    Arthur, DC
    Pettenati, MJ
    Patil, SR
    Rao, KW
    Watson, MS
    Koduru, PRK
    Moore, JO
    Stone, RM
    Mayer, RJ
    Feldman, EJ
    Davey, FR
    Schiffer, CA
    Larson, RA
    Bloomfield, CD
    [J]. BLOOD, 2002, 100 (13) : 4325 - 4336
  • [8] TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics
    Campo, Elias
    Cymbalista, Florence
    Ghia, Paolo
    Jaeger, Ulrich
    Pospisilova, Sarka
    Rosenquist, Richard
    Schuh, Anna
    Stilgenbauer, Stephan
    [J]. HAEMATOLOGICA, 2018, 103 (12) : 1956 - 1968
  • [9] FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor
    Chillón, MC
    Fernández, C
    García-Sanz, R
    Balanzategui, A
    Ramos, F
    Fernández-Calvo, J
    González, M
    San Miguel, JSF
    [J]. HEMATOLOGY JOURNAL, 2004, 5 (03) : 239 - 246
  • [10] Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients
    Chotirat, Sadudee
    Thongnoppakhun, Wanna
    Promsuwicha, Orathai
    Boonthimat, Chetsada
    Auewarakul, Chirayu U.
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2012, 5